Research programme: antisense drug therapies - Ionis Pharmaceuticals/Janssen Biotech
Latest Information Update: 28 Feb 2019
At a glance
- Originator Ionis Pharmaceuticals
- Class Antisense oligonucleotides
- Mechanism of Action Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders
Most Recent Events
- 28 Feb 2019 No recent reports of development identified for research development in Autoimmune-disorders in USA (Intragastric)
- 28 Feb 2019 No recent reports of development identified for research development in Autoimmune-disorders in USA (PO)
- 18 Dec 2015 Isis Pharmaceuticals is now called Ionis Pharmaceuticals